Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study
Open Access
- 29 November 2022
- journal article
- research article
- Published by Elsevier in Brain and Development
- Vol. 45 (3) , 161-170
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Nusinersen in patients older than 7 months with spinal muscular atrophy type 1Neurology, 2018
- Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gapsDevelopmental Medicine & Child Neurology, 2018
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2018
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2017
- Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophyBMC Neurology, 2017
- Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trialsNeuromuscular Disorders, 2016
- 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7–9 November 2014, Heemskerk, The NetherlandsNeuromuscular Disorders, 2015
- Spinal Muscular AtrophyArchives of Neurology, 2011
- Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelGenes & Development, 2010
- Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathyNeuromuscular Disorders, 2005